Loading...

Home
ETF
02367

02367

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

02367 News

CMSI Lowers GIANT BIOGENE Rating to Neutral and Reduces Target Price to HKD34.5

Dec 23 2025aastocks

M Stanley Lowers GIANT BIOGENE (02367.HK) Price Target to $42, Anticipates Boost in Sales from Enhanced Marketing Efforts

Dec 17 2025aastocks

UBS Lowers GIANT BIOGENE (02367.HK) Rating to Neutral and Reduces Price Target to $39.5

Dec 11 2025aastocks

HSBC Research Lowers GIANT BIOGENE's Target Price to HKD46.4, Maintains Buy Rating

Dec 05 2025aastocks

CICC Lowers GIANT BIOGENE's Target Price to HKD56, Remains Positive on Medium- to Long-Term Growth Prospects

Dec 04 2025aastocks

CMBI Lowers Price Target for GIANT BIOGENE (02367.HK) to $53.89, Maintains Buy Rating

Dec 04 2025aastocks

CICC Optimistic About GIANT BIOGENE's Long-Term Growth Prospects; Anticipates Product Line Expansion by 2026

Dec 03 2025aastocks

Citi Reduces Target Price for GIANT BIOGENE to HKD44.6, Maintains Buy Rating

Dec 03 2025aastocks

BofAS Lowers Price Target for GIANT BIOGENE (02367.HK) to $55.5, Maintains Buy Rating

Dec 03 2025aastocks

GIANT BIOGENE Soars 13% in Heavy Trading After Midday, Plans to Repurchase Up to 10% of Outstanding Shares

Dec 02 2025aastocks

CMBI Ratings and Target Prices for Chinese Pharmaceutical Companies (Table)

Nov 11 2025aastocks

CMBI Anticipates Recovery in Second Half Results for CXO Companies, Preferring SINO BIOPHARM and WUXI XDC

Nov 11 2025aastocks

New Consumers Excel as POP MART Rises 5%; AUNTEA JENNY Jumps Over 11% Due to Incentive Program

Nov 10 2025aastocks

CMBI Lowers GIANT BIOGENE's Target Price to HKD58.35; Maintains Buy Rating

Oct 24 2025aastocks

GIANT BIOGENE (02367.HK) Shares Surge Over 8% Following Stake Increase by Controlling Shareholder

Oct 23 2025aastocks

Net Inflow of HKD1.1 Billion in Southbound Trading for XIAOMI-W

Oct 16 2025aastocks